These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9790303)

  • 1. How does cytopathicity affect the production of neutralizing antibody?
    Keşmir C; De Boer RJ
    Scand J Immunol; 1998 Oct; 48(4):347-9. PubMed ID: 9790303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected].
    Planz O; Seiler P; Hengartner H; Zinkernagel RM
    Nature; 1996 Aug; 382(6593):726-9. PubMed ID: 8751445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do mathematical models tell us about killing rates during HIV-1 infection?
    Gadhamsetty S; Beltman JB; de Boer RJ
    Immunol Lett; 2015 Nov; 168(1):1-6. PubMed ID: 26279491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On immunological memory.
    Zinkernagel RM; Bachmann MF; Kündig TM; Oehen S; Pirchet H; Hengartner H
    Annu Rev Immunol; 1996; 14():333-67. PubMed ID: 8717518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antibody tag-team: driving neutralization through escape.
    Alter G; Ackerman ME
    Trends Immunol; 2014 Sep; 35(9):403-5. PubMed ID: 25131302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies and B cell memory in viral immunity.
    Dörner T; Radbruch A
    Immunity; 2007 Sep; 27(3):384-92. PubMed ID: 17892847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of HIV-1 replication in autologous CD4
    Tu T; Zhan J; Mou D; Li W; Su B; Zhang T; Li T; Li N; Wu H; Jin C; Chen H
    Virol Sin; 2017 Dec; 32(6):485-494. PubMed ID: 28918477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.
    Iseda S; Takahashi N; Poplimont H; Nomura T; Seki S; Nakane T; Nakamura M; Shi S; Ishii H; Furukawa S; Harada S; Naruse TK; Kimura A; Matano T; Yamamoto H
    J Virol; 2016 Jul; 90(14):6276-6290. PubMed ID: 27122584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes.
    Barnaba V; Franco A; Alberti A; Benvenuto R; Balsano F
    Nature; 1990 May; 345(6272):258-60. PubMed ID: 2110296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
    Pier GB; Takeda S; Grout M; Markham RB
    J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.
    Liu MA; Kranz DM; Kurnick JT; Boyle LA; Levy R; Eisen HN
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8648-52. PubMed ID: 3936039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization.
    Ahlers JD; Dunlop N; Pendleton CD; Newman M; Nara PL; Berzofsky JA
    AIDS Res Hum Retroviruses; 1996 Mar; 12(4):259-72. PubMed ID: 8906986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of Fc receptors of lymphocytes, macrophages and other mammalian cells in immune processes].
    Liampert IM
    Usp Sovrem Biol; 1982; 94(1):67-82. PubMed ID: 6753399
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-infection immunodeficiency virus control by neutralizing antibodies.
    Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
    PLoS One; 2007 Jun; 2(6):e540. PubMed ID: 17579714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defense mechanisms against primary influenza virus infection in mice. I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production.
    Iwasaki T; Nozima T
    J Immunol; 1977 Jan; 118(1):256-63. PubMed ID: 401512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mathematical model on germinal center kinetics and termination.
    Keşmir C; De Boer RJ
    J Immunol; 1999 Sep; 163(5):2463-9. PubMed ID: 10452981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunological mechanisms in thyrotoxicosis].
    Bradistilov S
    Vutr Boles; 1979; 18(2):9-16. PubMed ID: 380170
    [No Abstract]   [Full Text] [Related]  

  • 19. Kinetics of protective antibodies are determined by the viral surface antigen.
    Pinschewer DD; Perez M; Jeetendra E; Bächi T; Horvath E; Hengartner H; Whitt MA; de la Torre JC; Zinkernagel RM
    J Clin Invest; 2004 Oct; 114(7):988-93. PubMed ID: 15467838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides.
    Boudewijns M; Jeurissen A; Wuyts M; Moens L; Boon L; Van Neerven JJ; Kasran A; Overbergh L; Lenaerts C; Waer M; Mathieu C; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2005 Nov; 78(5):1060-9. PubMed ID: 16081596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.